Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.

Trial Details

NCT ID
NCT07277322
Phase
PHASE1 / PHASE2
Sponsor
Dan Feng
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Dupilumab
  • Toripalimab
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histological diagnosis of non-MSI-H/pMMR CRC
  • Subjects who have biology-proven non-MSI-H/pMMR CRC and with radiographic findings suggestive of liver metastases may be eligible.
  • Resectable liver metastases including:
  • synchronous liver metastases (present at the time of diagnosis of MSS CRC) and treatment-naïve

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →